NEW YORK (GenomeWeb News) — Biomarker research company Miraculins today said it has made an unsolicited offer to acquire Montreal-based IBEX, a cancer and arthritis diagnostics company.

 

"The cancer diagnostic programs of Miraculins and IBEX are extremely complementary, and future opportunities for our companies are enhanced by this transaction", Miraculins President Jim Charlton said in a statement.